Lalka D, Meyer M B, Duce B R, Elvin A T
Clin Pharmacol Ther. 1976 Jun;19(6):757-66. doi: 10.1002/cpt1976196757.
Tocainide, a primary amine analogue of lidocaine, is effective against some experimental and clinical arrhythmias. Its pharmacokinetic behavior was studied in 6 healthy male subjects. Peak blood levels (CB max) and area under the blood concentration-time curve (AUC) were linearly related to dose with slopes of 0.0067 mcg/ml and 6 min mcg/ml per milligram of dose, respectively. Renal clearance of tocainide averaged 59 ml/min when urinary pH was uncontrolled or acidified, while it was reduced to 13 ml/min during intense sodium bicarbonate loading. Blood levels following intravenous infusion were well described by a 2-compartment open model with a volume of the central compartment of 0.92 L/kg. The t 1/2 beta was 11 hr and total body clearance was 166 ml/min. Loo-Riegelman analysis of the absorption rate did not allow unequivocal assignment of an "order" to the absorption process. Bioavailability approached 100%. Administration of drug 5 min after a test meal suppressed CB max 40% but minimally affected AUC. Approximately 50% of the drug was found to be plasma protein bound at clinically effective concentrations.
妥卡尼是利多卡因的伯胺类似物,对某些实验性和临床心律失常有效。在6名健康男性受试者中研究了其药代动力学行为。血药峰浓度(CB max)和血药浓度-时间曲线下面积(AUC)与剂量呈线性关系,斜率分别为0.0067 mcg/ml和每毫克剂量6 min mcg/ml。当尿液pH值未控制或酸化时,妥卡尼的肾清除率平均为59 ml/min,而在大量输注碳酸氢钠期间,肾清除率降至13 ml/min。静脉输注后的血药浓度可用二室开放模型很好地描述,中央室容积为0.92 L/kg。t 1/2 beta为11小时,全身清除率为166 ml/min。用Loo-Riegelman法分析吸收速率无法明确确定吸收过程的“级数”。生物利用度接近100%。在试验餐后5分钟给药可使CB max降低40%,但对AUC影响极小。在临床有效浓度下,约50%的药物与血浆蛋白结合。